thiotepa
Commercial- Indications
- Cancer
Company intelligence / Profile preview
Sichuan Huiyu Seacross Pharma Technology Ltd.
Sichuan Sheng, Chinaen.huiyupharma.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has two drug candidates (HY-0005 and HY0001a) at the IND Application stage as of May 2025[2]
- Therapeutic areas
- Oncology
- Modalities
- Antibody drug conjugate (ADC)Trispecific T-cell engager (TriTE)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Sichuan Huiyu Seacross Pharma Technology Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sichuan Huiyu Seacross Pharma Technology Ltd..